As of November 14, 2026, Cidara Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 7, 2026 (Form 8-K, January 7, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Cidara Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cidara Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-07. Every row below is cited to the filing it comes from, and this page adds each new change as Cidara Therapeutics, Inc. files it.
Layoffs on record: about 20 jobs, latest 2024-09-12 (layoff filings and notices).
Also on the record for Cidara Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by BCLS Fund III Investments, LP | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 1.4% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Vivo Opportunity Fund Holdings, L.P. | — | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 6.38% of the class | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | — | 5%+ stakes | Source |
| January 7, 2026 | Acquired by Merck Sharp & Dohme LLC | — | Acquisition | Source |
| November 17, 2025 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 10.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by BCLS Fund III Investments, LP | 9.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Commodore Capital LP | 2% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Paradigm BioCapital Advisors LP | 3.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 6.2% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by TCG Crossover GP II, LLC | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cidara Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cidara Therapeutics, Inc. and the records around it.
Cidara Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
- Acquisition Jan 2026
- Who owns it
Companies that share a holder
- BCLS Fund III Investments, LP also filed stake reports on 3 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Heartflow, Inc. (Aug 2026), DIANTHUS THERAPEUTICS, INC. (Nov 2025)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Cidara Therapeutics, Inc.
Get an email when Cidara Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cidara Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cidara Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cidara Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 26 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-07 | Reported | not named in the filing | 8-K, 2026-01-07 |
New leaders reset buying decisions — get the Full Report on Cidara Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Cidara Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Cidara Therapeutics, Inc.Every change, in the filing's words
Reported
In accordance with the terms of the Merger Agreement, effective as of the Effective Time, (i) the directors of Purchaser as of immediately prior to the Effective Time, Jon Filderman, Melissa Leonard and Dalton Smart became the directors of the Company until the earlier of their resignation or removal or until their respective successors are duly designated, as the case may be, and each of Daniel Burgess, Bonnie Bassler, Carin Canale-Theakston, James Merson, Chrysa Mineo, Joshua Resnick, Theodore R. Schroeder, Ryan Spencer and Jeffrey Stein voluntarily resigned as directors of the Company and f
- Information with respect to the new officers and directors of the Company is set forth in Schedule I to the Offer to Purchase, a copy of which is attached as Exhibit (a)(1)(i) to the Schedule TO filed by Parent and Purchaser on December 5, 2025.
Tools for this story
Each opens in a new tab, filled in for Cidara Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
